Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 538 articles:
HTML format
Text format



Single Articles


    April 2018
  1. HAN S, Woo S, Kim YJ, Suh CH, et al
    Impact of (68)Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2018 Apr 17. pii: S0302-2838(18)30248.
    PubMed     Text format     Abstract available


  2. NUHN P, De Bono JS, Fizazi K, Freedland SJ, et al
    Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Eur Urol. 2018 Apr 16. pii: S0302-2838(18)30246.
    PubMed     Text format     Abstract available


  3. VAN LEEUWEN PJ, van der Poel HG
    Re: Karim A. Touijer, Robert Jeffery Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol. In p
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30258.
    PubMed     Text format    


  4. VAN STAM MA, van der Poel H
    The New Standard: Personalised Information about the Risks and Benefits of Treatment Strategies for Localised Prostate Cancer.
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30199.
    PubMed     Text format    


  5. REICHARD CA, Gregg JR, Achim MF, Aparicio AM, et al
    Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30249.
    PubMed     Text format     Abstract available


  6. ALCARAZ A, Mengual L
    Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30256.
    PubMed     Text format    


  7. HAIDL F, Heidenreich A, Pfister D
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 10. pii: S0302-2838(18)30247.
    PubMed     Text format    


  8. VILLERS A, Olivier J
    Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30242.
    PubMed     Text format    


  9. GIANNARINI G, Fossati N, Gandaglia G, Cucchiara V, et al
    Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30202.
    PubMed     Text format    


  10. MAURER T, Robu S, Schottelius M, Schwamborn K, et al
    (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30189.
    PubMed     Text format     Abstract available


  11. CARNEIRO A, Sanchez-Salas R
    Re: Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30204.
    PubMed     Text format    


    March 2018
  12. LAVORGNA G, Montorsi F, Salonia A
    Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. Nat Genet 2018;50:219-28: Lipid Metabolism in Prostate Cancer: Expanding Patient Ther
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30181.
    PubMed     Text format    


  13. EKLUND M, Strom P, Nordstrom T, Gronberg H, et al
    Reply to Ola Bratt and Anna Ofverholm's Letter to the Editor re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. E
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30185.
    PubMed     Text format    


  14. TOSOIAN JJ, Lotan TL
    The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30188.
    PubMed     Text format    


  15. BRATT O, Ofverholm A
    Re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.0
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30186.
    PubMed     Text format    


  16. KINSELLA N, Stattin P, Cahill D, Brown C, et al
    Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30176.
    PubMed     Text format     Abstract available


  17. VAN SOEST RJ, Tombal B, Lolkema MP, de Wit R, et al
    Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30178.
    PubMed     Text format    


  18. PANEBIANCO V, Barchetti G, Simone G, Del Monte M, et al
    Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30183.
    PubMed     Text format     Abstract available


  19. HAO J, Ci X, Xue H, Wu R, et al
    Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Mar 12. pii: S0302-2838(18)30162.
    PubMed     Text format     Abstract available


  20. MONTGOMERY B, Lin DW
    Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding Road.
    Eur Urol. 2018 Mar 8. pii: S0302-2838(18)30164.
    PubMed     Text format    


  21. DAVIS ID
    Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2018 Mar 7. pii: S0302-2838(18)30163.
    PubMed     Text format    


  22. SJOBERG DD, Vickers AJ, Assel M, Dahlin A, et al
    Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Eur Urol. 2018 Mar 5. pii: S0302-2838(18)30126.
    PubMed     Text format     Abstract available


    February 2018
  23. TYSON MD 2ND, Koyama T, Lee D, Hoffman KE, et al
    Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Eur Urol. 2018 Feb 28. pii: S0302-2838(18)30119.
    PubMed     Text format     Abstract available


  24. MEHRA N, Dolling D, Sumanasuriya S, Christova R, et al
    Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Eur Urol. 2018 Feb 27. pii: S0302-2838(18)30120.
    PubMed     Text format     Abstract available


  25. MAHAL BA, Yang DD, Wang NQ, Alshalalfa M, et al
    Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Eur Urol. 2018 Feb 22. pii: S0302-2838(18)30098.
    PubMed     Text format     Abstract available


  26. GRAVIS G, Boher JM, Chen YH, Liu G, et al
    Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Eur Urol. 2018 Feb 20. pii: S0302-2838(18)30102.
    PubMed     Text format     Abstract available


  27. CHANDRASEKAR T, Ost P, Tilki D
    Is (68)Ga-Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?
    Eur Urol. 2018 Feb 19. pii: S0302-2838(18)30083.
    PubMed     Text format    


  28. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2.
    Eur Urol. 2018 Feb 17. pii: S0302-2838(18)30110.
    PubMed     Text format    


  29. AGGARWAL R
    Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30112.
    PubMed     Text format    


  30. LAMB AD, Bryant RJ, Mills IG, Hamdy FC, et al
    First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30114.
    PubMed     Text format    


  31. MOROTE J, Comas I, Planas J
    Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.
    Eur Urol. 2018 Feb 13. pii: S0302-2838(18)30093.
    PubMed     Text format    


  32. HAESE A
    Re: Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30086.
    PubMed     Text format    


  33. ANTONARAKIS ES, Lu C, Luber B, Liang C, et al
    Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30089.
    PubMed     Text format     Abstract available


  34. COOPERBERG MR, Brooks JD, Faino AV, Newcomb LF, et al
    Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30067.
    PubMed     Text format     Abstract available


  35. FAIENA I, Salmasi A, Pantuck AJ, Drakaki A, et al
    Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30077.
    PubMed     Text format    


  36. AMINSHARIFI A, Polascik TJ
    Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.
    Eur Urol. 2018 Feb 7. pii: S0302-2838(18)30076.
    PubMed     Text format    


  37. COOPERBERG MR
    How Should a Man with Prostate Cancer Choose his Surgeon?
    Eur Urol. 2018 Feb 3. pii: S0302-2838(18)30074.
    PubMed     Text format    


  38. WINTER A, Chavan A, Wawroschek F
    Magnetic Resonance Imaging of Sentinel Lymph Nodes Using Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer Patients: First-in-human Results.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30018.
    PubMed     Text format    


  39. TO SQ, Kwan EM, Fettke HC, Mant A, et al
    Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30016.
    PubMed     Text format     Abstract available


    January 2018
  40. TEMIZ MZ, Besiroglu H
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2018 Jan 31. pii: S0302-2838(18)30023.
    PubMed     Text format    


  41. KAPOOR DA
    Prostate Cancer Care and Practice Patterns: Low-quality Observations Miss the Benefits from High-quality Care.
    Eur Urol. 2018 Jan 30. pii: S0302-2838(18)30006.
    PubMed     Text format    


  42. MATEO J, Cheng HH, Beltran H, Dolling D, et al
    Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
    Eur Urol. 2018 Jan 29. pii: S0302-2838(18)30019.
    PubMed     Text format     Abstract available


  43. AHLGREN GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, et al
    Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30021.
    PubMed     Text format     Abstract available


  44. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30024.
    PubMed     Text format    


  45. RAUSCHER I, Duwel C, Haller B, Rischpler C, et al
    Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Eur Urol. 2018 Jan 18. pii: S0302-2838(18)30010.
    PubMed     Text format     Abstract available


  46. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jan 17. pii: S0302-2838(18)30005.
    PubMed     Text format     Abstract available


  47. STROM P, Nordstrom T, Gronberg H, Eklund M, et al
    The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Eur Urol. 2018 Jan 10. pii: S0302-2838(17)31096.
    PubMed     Text format     Abstract available


  48. UO T, Sprenger C
    Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward.
    Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31067.
    PubMed     Text format    


    December 2017
  49. BOSSI A
    Re: Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    Eur Urol. 2017 Dec 26. pii: S0302-2838(17)31046.
    PubMed     Text format    


  50. FRASER M, Boutros PC, Bristow RG
    A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31021.
    PubMed     Text format    


  51. ROACH M RD
    Re: Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31041.
    PubMed     Text format    


  52. ZHANG Q, Helfand BT, Carneiro BA, Qin W, et al
    Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-beta Insensitive Genetically Targeted CD8(+) T-cells Derived from Patients with Metastatic Castrate-resistant Disease.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31040.
    PubMed     Text format     Abstract available


  53. ROCCO B, Eissa A, Bianchi G
    Re: Positron Emission Tomography/Computed Tomography-based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31036.
    PubMed     Text format    


  54. OZEN H, Turkeri LN
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31044.
    PubMed     Text format    


  55. LUO J, Attard G, Balk SP, Bevan C, et al
    Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Eur Urol. 2017 Dec 16. pii: S0302-2838(17)31030.
    PubMed     Text format     Abstract available


  56. ROBINSON D, Garmo H, Lissbrant IF, Widmark A, et al
    Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.
    Eur Urol. 2017 Dec 15. pii: S0302-2838(17)31031.
    PubMed     Text format     Abstract available


  57. SPRATT DE, Dai DLY, Den RB, Troncoso P, et al
    Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31016.
    PubMed     Text format     Abstract available


  58. VALE C, Fisher D, Tierney J, White I, et al
    Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analy
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31019.
    PubMed     Text format    


  59. WALLIS CJD, Klaassen Z
    Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androge
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31020.
    PubMed     Text format    


  60. DONG L, Pienta KJ
    Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31023.
    PubMed     Text format    


    November 2017
  61. HAMDY FC, Lamb AD, Bryant RJ
    Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30994.
    PubMed     Text format    


  62. COOPERBERG MR
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30982.
    PubMed     Text format    


  63. ABDOLLAH F, Dalela D, Menon M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 22. pii: S0302-2838(17)30985.
    PubMed     Text format    


  64. LOEB S
    Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.
    Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30976.
    PubMed     Text format    


  65. CRUMBAKER M, Savdie R, Joshua AM
    Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.
    Eur Urol. 2017 Nov 18. pii: S0302-2838(17)30981.
    PubMed     Text format    


  66. MARTINI A, Gupta A, Cumarasamy S, Tewari AK, et al
    Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. In p
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30974.
    PubMed     Text format    


  67. LAMB AD, Bryant RJ, Camilleri P, Hamdy FC, et al
    Orient Expression: Solving the Mystery of Asian Prostate Cancer?
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30969.
    PubMed     Text format    


  68. LAVORGNA G, Montorsi F, Salonia A
    Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30973.
    PubMed     Text format    


  69. CUCCHIARA V, Cooperberg MR, Dall'Era M, Lin DW, et al
    Genomic Markers in Prostate Cancer Decision Making.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30975.
    PubMed     Text format     Abstract available


  70. TOMBAL B
    Assembling the Puzzle of Advanced Prostate Cancer: Lessons from GETUG-AFU 15.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30968.
    PubMed     Text format    


  71. AGGARWAL R
    Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30967.
    PubMed     Text format    


  72. RAMEY SJ, Agrawal S, Abramowitz MC, Moghanaki D, et al
    Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30900.
    PubMed     Text format     Abstract available


  73. CULINE S
    Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30907.
    PubMed     Text format    


  74. IBRAGIMOVA N, Zhanzak Z, Meyerbekova A, Xie Y, et al
    Re: Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Nov 4. pii: S0302-2838(17)30910.
    PubMed     Text format    


  75. MOTTET N, De Santis M, Briers E, Gillessen S, et al
    Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
    Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839.
    PubMed     Text format     Abstract available


    October 2017
  76. HEINZELBECKER J, Stockle M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30899.
    PubMed     Text format    


  77. SPRATT DE, Dess RT, Feng FY
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Can
    Eur Urol. 2017 Oct 27. pii: S0302-2838(17)30897.
    PubMed     Text format    


  78. LAVAUD P, Gravis G, Foulon S, Joly F, et al
    Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naive Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Eur Urol. 2017 Oct 23. pii: S0302-2838(17)30791.
    PubMed     Text format     Abstract available


  79. ASSEL M, Dahlin A, Ulmert D, Bergh A, et al
    Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Eur Urol. 2017 Oct 21. pii: S0302-2838(17)30860.
    PubMed     Text format     Abstract available


  80. SAITO K, Fujii Y
    Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.
    Eur Urol. 2017 Oct 20. pii: S0302-2838(17)30858.
    PubMed     Text format    


  81. GHADJAR P, Wiegel T
    Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017
    Eur Urol. 2017 Oct 19. pii: S0302-2838(17)30861.
    PubMed     Text format    


  82. GOOD DW, McNeill AS
    Re: Impact of Radical Prostatectomy on Long-term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.
    Eur Urol. 2017 Oct 17. pii: S0302-2838(17)30844.
    PubMed     Text format    


  83. VAN DER KWAST T
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30842.
    PubMed     Text format    


  84. TOUIJER KA, Karnes RJ, Passoni N, Sjoberg DD, et al
    Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30828.
    PubMed     Text format     Abstract available


  85. MCLEOD DG, Petrovics G
    Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30845.
    PubMed     Text format    


  86. WALLIS CJD, Klaassen Z, Bhindi B, Goldberg H, et al
    Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30849.
    PubMed     Text format     Abstract available


  87. SPAHN M
    Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30843.
    PubMed     Text format    


  88. PLOUSSARD G
    Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30841.
    PubMed     Text format    


  89. VAN DEN EEDEN SK, Lu R, Zhang N, Quesenberry CP Jr, et al
    A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Eur Urol. 2017 Oct 5. pii: S0302-2838(17)30777.
    PubMed     Text format     Abstract available


    September 2017
  90. WALZ J
    The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis?
    Eur Urol. 2017 Sep 28. pii: S0302-2838(17)30779.
    PubMed     Text format    


  91. PANSADORO V, Brassetti A
    Re: Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30782.
    PubMed     Text format    


  92. CAPOGROSSO P, Montorsi F
    Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30726.
    PubMed     Text format    


  93. GASSER T
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System.
    Eur Urol. 2017 Sep 20. pii: S0302-2838(17)30727.
    PubMed     Text format    


  94. MILLER K, Carles J, Gschwend JE, Van Poppel H, et al
    The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Eur Urol. 2017 Sep 19. pii: S0302-2838(17)30728.
    PubMed     Text format     Abstract available


  95. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30711.
    PubMed     Text format     Abstract available


  96. REN S, Wei GH, Liu D, Wang L, et al
    Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.
    Eur Urol. 2017 Sep 15. pii: S0302-2838(17)30720.
    PubMed     Text format     Abstract available


  97. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen Afte
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30719.
    PubMed     Text format    


  98. SEISEN T, Vetterlein MW, Karabon P, Jindal T, et al
    Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis.
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30697.
    PubMed     Text format     Abstract available


  99. DAL PRA A, Supiot S, Ghadjar P
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30718.
    PubMed     Text format    


    August 2017
  100. ZHU Y, Sharp A, Anderson CM, Silberstein JL, et al
    Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Aug 30. pii: S0302-2838(17)30695.
    PubMed     Text format     Abstract available


  101. GILLESSEN S, de Bono JS, Sartor O, Omlin AG, et al
    Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30700.
    PubMed     Text format    


  102. VON EYBEN FE, Virgolini I, Roviello G
    Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30696.
    PubMed     Text format    


  103. EGGER SJ, Calopedos RJ, O'Connell DL, Chambers SK, et al
    Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30699.
    PubMed     Text format     Abstract available


  104. TAKEDA T, Tin AL, Corradi RB, Mamoor M, et al
    Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30691.
    PubMed     Text format     Abstract available


  105. BORGMANN H, Lallous N, Ozistanbullu D, Beraldi E, et al
    Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30698.
    PubMed     Text format     Abstract available


  106. DE BONO JS, Chowdhury S, Feyerabend S, Elliott T, et al
    Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for >/=24 weeks in Europe.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30664.
    PubMed     Text format     Abstract available


  107. LOEB S, Zhou Q, Siebert U, Rochau U, et al
    Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30642.
    PubMed     Text format     Abstract available


  108. HOLLENBECK BK, Kaufman SR, Yan P, Herrel LA, et al
    Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
    Eur Urol. 2017 Aug 17. pii: S0302-2838(17)30687.
    PubMed     Text format     Abstract available


  109. SEITZ AK, Thoene S, Bietenbeck A, Nawroth R, et al
    AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Eur Urol. 2017 Aug 14. pii: S0302-2838(17)30653.
    PubMed     Text format     Abstract available


  110. WOO S, Suh CH, Kim SY
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cance
    Eur Urol. 2017 Aug 11. pii: S0302-2838(17)30669.
    PubMed     Text format    


  111. DEL RE M, Biasco E, Crucitta S, Derosa L, et al
    Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resi
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30663.
    PubMed     Text format    


  112. MESSINA C, Messina M, Boccardo F
    Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30659.
    PubMed     Text format    


  113. AYUBI E, Safiri S
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30668.
    PubMed     Text format    


  114. DE GIORGI U, Conteduca V, Scarpi E
    Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30661.
    PubMed     Text format    


  115. KLEIN EA
    Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30644.
    PubMed     Text format    


  116. DOWNER MK
    Why Epidemiological Studies of Physical Activity in Prostate Cancer Often Underestimate its Benefits.
    Eur Urol. 2017 Aug 3. pii: S0302-2838(17)30656.
    PubMed     Text format    


  117. FRIEDLANDER DF, Trinh QD, Krasnova A, Lipsitz SR, et al
    Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics.
    Eur Urol. 2017 Aug 1. pii: S0302-2838(17)30652.
    PubMed     Text format     Abstract available


    July 2017
  118. AGGARWAL R, Vigneron DB, Kurhanewicz J
    Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
    Eur Urol. 2017 Jul 29. pii: S0302-2838(17)30651.
    PubMed     Text format    


  119. AGGARWAL A, Lewis D, Charman SC, Mason M, et al
    Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition.
    Eur Urol. 2017 Jul 28. pii: S0302-2838(17)30601.
    PubMed     Text format     Abstract available


  120. LARDAS M, Liew M, van den Bergh RC, De Santis M, et al
    Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
    Eur Urol. 2017 Jul 27. pii: S0302-2838(17)30535.
    PubMed     Text format     Abstract available


  121. TREE A, Dearnaley D
    Randomised Controlled Trials Remain the Key to Progress in Localised Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30590.
    PubMed     Text format    


  122. CROOK J
    Optimal Radiotherapy for Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30589.
    PubMed     Text format    


  123. PENSON DF
    Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not.
    Eur Urol. 2017 Jul 20. pii: S0302-2838(17)30588.
    PubMed     Text format    


  124. CARAM MEV, Miller DC
    Treating Advanced Prostate Cancer-the Human Factor.
    Eur Urol. 2017 Jul 18. pii: S0302-2838(17)30585.
    PubMed     Text format    


  125. SPRATT DE, Dess RT, Zumsteg ZS, Lin DW, et al
    A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
    Eur Urol. 2017 Jul 14. pii: S0302-2838(17)30527.
    PubMed     Text format     Abstract available


  126. WANG Y, Jacobs EJ, Gapstur SM, Maliniak ML, et al
    Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
    Eur Urol. 2017 Jul 12. pii: S0302-2838(17)30537.
    PubMed     Text format     Abstract available


  127. PARKER CC, Coleman RE, Sartor O, Vogelzang NJ, et al
    Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516.
    PubMed     Text format     Abstract available


  128. LUO J, Luber B, Wang H, Antonarakis ES, et al
    Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30532.
    PubMed     Text format    


  129. GALFANO A, Secco S, Bocciardi AM
    Will Retzius-sparing Prostatectomy Be the Future of Prostate Cancer Surgery?
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30523.
    PubMed     Text format    


  130. KIM JH, Lee B, Chung BI
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 Jul 6. pii: S0302-2838(17)30524.
    PubMed     Text format    


  131. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and S
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30531.
    PubMed     Text format    


  132. JOHNSON SB, Lester-Coll NH, Kelly JR, Kann BH, et al
    Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30515.
    PubMed     Text format     Abstract available


  133. WOO S, Suh CH, Kim SY
    Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30525.
    PubMed     Text format    


  134. HABIBZADEH P, Habibzadeh F
    Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based
    Eur Urol. 2017 Jul 4. pii: S0302-2838(17)30528.
    PubMed     Text format    


    June 2017
  135. GILLESSEN S, Attard G, Beer TM, Beltran H, et al
    Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    Eur Urol. 2017 Jun 24. pii: S0302-2838(17)30497.
    PubMed     Text format     Abstract available


  136. ALBERTS AR, Schoots IG, Bokhorst LP, Drost FH, et al
    Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic R
    Eur Urol. 2017 Jun 21. pii: S0302-2838(17)30514.
    PubMed     Text format     Abstract available


  137. D'ANDREA D, Shariat SF
    Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Jun 20. pii: S0302-2838(17)30513.
    PubMed     Text format    


  138. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    Reply to Isabel Heidegger, Renate Pichler, and Andreas Pircher's Letter to the Editor re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relations
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30504.
    PubMed     Text format    


  139. TREE AC, Siva S, Ost P
    Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3.
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30506.
    PubMed     Text format    


  140. GANDAGLIA G, Boorjian SA, Parker WP, Zaffuto E, et al
    Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2017 Jun 13. pii: S0302-2838(17)30496.
    PubMed     Text format     Abstract available


  141. WALLIS CJD, Glaser A, Hu JC, Huland H, et al
    Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.
    Eur Urol. 2017 Jun 10. pii: S0302-2838(17)30495.
    PubMed     Text format     Abstract available


  142. HOYLE AP, Clarke NW
    Magnetic Resonance Imaging and Detection of Metastases in Prostate Cancer: Learning Lessons from History.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30492.
    PubMed     Text format    


  143. ALBERTSEN PC
    Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30485.
    PubMed     Text format    


  144. HEIDEGGER I, Pichler R, Pircher A
    Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30493.
    PubMed     Text format    


  145. CLARKE NW
    Re: Nicola Fossati, Peter-Paul M. Willemse, Thomas Van den Broeck, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. In Press. http://dx.doi.org
    Eur Urol. 2017 Jun 1. pii: S0302-2838(17)30410.
    PubMed     Text format    


  146. MANDEL P, Preisser F, Graefen M, Steuber T, et al
    High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy.
    Eur Urol. 2017;71:848-850.
    PubMed     Text format     Abstract available


  147. HEESAKKERS J, Farag F, Bauer RM, Sandhu J, et al
    Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review.
    Eur Urol. 2017;71:936-944.
    PubMed     Text format     Abstract available


    May 2017
  148. TROCK BJ, Karnes RJ
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 May 31. pii: S0302-2838(17)30464.
    PubMed     Text format    


  149. AYUBI E, Safiri S
    Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30465.
    PubMed     Text format    


  150. WOO S, Suh CH, Kim SY
    Reply to Thorsten Derlin, Christoph-A. von Klot, and Katja Hueper's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Met
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30470.
    PubMed     Text format    


  151. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30451.
    PubMed     Text format    


  152. DERLIN T, von Klot CA, Hueper K
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30469.
    PubMed     Text format    


  153. REICHARD CA, Chapin BF
    Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?
    Eur Urol. 2017 May 25. pii: S0302-2838(17)30404.
    PubMed     Text format    


  154. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30402.
    PubMed     Text format    


  155. COOPERBERG MR
    The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30401.
    PubMed     Text format     Abstract available


  156. WANG R, Sun Y, Li L, Niu Y, et al
    Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(R) to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30285.
    PubMed     Text format     Abstract available


  157. NGUYEN PL, Haddad Z, Ross AE, Martin NE, et al
    Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30390.
    PubMed     Text format     Abstract available


  158. HERMANNS T, Poyet C
    The Next Generation of Prostate Cancer Risk Calculators.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30387.
    PubMed     Text format    


  159. BECK M, Hayoz S, Ghadjar P
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30385.
    PubMed     Text format    


  160. HADASCHIK B, Herrmann K
    Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30388.
    PubMed     Text format    


  161. CHUA MLK, Lo W, Pintilie M, Murgic J, et al
    A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Eur Urol. 2017 May 13. pii: S0302-2838(17)30344.
    PubMed     Text format     Abstract available


  162. MITRAKAS L
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73.
    Eur Urol. 2017 May 10. pii: S0302-2838(17)30345.
    PubMed     Text format    


  163. MIRTTI T, Aittokallio T
    Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30340.
    PubMed     Text format    


  164. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prost
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30341.
    PubMed     Text format    


  165. LEAPMAN MS, Cowan JE, Simko J, Roberge G, et al
    Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
    Eur Urol. 2017;71:750-759.
    PubMed     Text format     Abstract available


  166. HE J, Albertsen PC, Moore D, Rotter D, et al
    Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
    Eur Urol. 2017;71:760-763.
    PubMed     Text format     Abstract available


  167. FROEHNER M, Koch R, Hubler M, Zastrow S, et al
    Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older.
    Eur Urol. 2017;71:710-713.
    PubMed     Text format     Abstract available


  168. BRAJTBORD JS, Leapman MS, Cooperberg MR
    The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.
    Eur Urol. 2017;71:705-709.
    PubMed     Text format     Abstract available


  169. TOSOIAN JJ, Almutairi F, Morais CL, Glavaris S, et al
    Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Eur Urol. 2017;71:697-700.
    PubMed     Text format     Abstract available


  170. KISHAN AU, Shaikh T, Wang PC, Reiter RE, et al
    Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Eur Urol. 2017;71:766-773.
    PubMed     Text format     Abstract available


  171. STUDENT V JR, Vidlar A, Grepl M, Hartmann I, et al
    Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy: One-year Functional Outcomes in a Two-group Randomised Controlled Trial.
    Eur Urol. 2017;71:822-830.
    PubMed     Text format     Abstract available


    April 2017
  172. YANG JC, Evans CP
    Adjunct Screening of NKX3.1 Expression Supports 5alpha-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.
    Eur Urol. 2017 Apr 25. pii: S0302-2838(17)30327.
    PubMed     Text format    


  173. PATEL DN, Freedland SJ
    New Prostate Cancer Biomarkers: The Search Continues.
    Eur Urol. 2017 Apr 24. pii: S0302-2838(17)30293.
    PubMed     Text format    


  174. WALSH PC
    The Search for the Missing Heritability of Prostate Cancer.
    Eur Urol. 2017 Apr 22. pii: S0302-2838(17)30283.
    PubMed     Text format     Abstract available


  175. GRUMMET JP, Plass K, N'Dow J
    Prostate Cancer Management in an Ageing Population.
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30290.
    PubMed     Text format    


  176. SOORIAKUMARAN P, Nyberg T, Akre O, Widmark A, et al
    Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Eur Urol. 2017 Apr 14. pii: S0302-2838(17)30282.
    PubMed     Text format     Abstract available


  177. SOOD A, Abdollah F
    Re: Diagnostic Accuracy of Multi-parametric Magnetic Resonance Imaging and Transrectal Ultrasound Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30275.
    PubMed     Text format    


  178. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30273.
    PubMed     Text format     Abstract available


  179. GANDAGLIA G, Fossati N, Zaffuto E, Bandini M, et al
    Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30280.
    PubMed     Text format     Abstract available


  180. WALKER SM, Knight LA, McCavigan AM, Logan GE, et al
    Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30238.
    PubMed     Text format     Abstract available


  181. RADTKE JP, Wiesenfarth M, Kesch C, Freitag MT, et al
    Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30267.
    PubMed     Text format     Abstract available


  182. KARNES RJ, Choeurng V, Ross AE, Schaeffer EM, et al
    Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264.
    PubMed     Text format     Abstract available


  183. KLEIN EA, Chait A, Hafron JM, Kernen KM, et al
    The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary
    Eur Urol. 2017 Apr 7. pii: S0302-2838(17)30236.
    PubMed     Text format     Abstract available



  184. Prostate Cancer and the John West Effect.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30095.
    PubMed     Text format     Abstract available


  185. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231.
    PubMed     Text format     Abstract available


  186. DUTTA A, Panja S, Virk RK, Kim JY, et al
    Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5alpha-reductase Inhibition.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30252.
    PubMed     Text format     Abstract available


  187. WEGELIN O, van Melick HHE, Hooft L, Bosch JLHR, et al
    Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Techniqu
    Eur Urol. 2017;71:517-531.
    PubMed     Text format     Abstract available


    March 2017
  188. SCHROECK FR, Jacobs BL, Bhayani SB, Nguyen PL, et al
    Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Eur Urol. 2017 Mar 30. pii: S0302-2838(17)30239.
    PubMed     Text format     Abstract available


  189. KIM JH, Khandwala YS, Chung BI
    Re: Jim C. Hu, David M. Nanus, Art Sedrakyan. Increase in prostate cancer metastases at radical prostatectomy in the United States. Eur Urol 2017;71:147-9.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30234.
    PubMed     Text format    


  190. SCHWEIZER MT, Antonarakis ES, Denmeade SR
    Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30233.
    PubMed     Text format     Abstract available


  191. PORTER LH, Lawrence MG, Ilic D, Clouston D, et al
    Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    Eur Urol. 2017 Mar 22. pii: S0302-2838(17)30178.
    PubMed     Text format     Abstract available


  192. LAMB BW, Violet J, Siva S, Murphy DG, et al
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30179.
    PubMed     Text format    


  193. MOLDOVAN PC, Van den Broeck T, Sylvester R, Marconi L, et al
    What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30115.
    PubMed     Text format     Abstract available


  194. MO F, Lin D, Takhar M, Ramnarine VR, et al
    Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Mar 19. pii: S0302-2838(17)30166.
    PubMed     Text format     Abstract available


  195. ALONGI F, Aiello D, Mazzola R, Cavalleri S, et al
    Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30169.
    PubMed     Text format    


  196. MOSCHINI M, Carroll PR, Eggener SE, Epstein JI, et al
    Low-risk Prostate Cancer: Identification, Management, and Outcomes.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30174.
    PubMed     Text format     Abstract available


  197. SMITH MR, Saad F, Rathkopf DE, Mulders PF, et al
    Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30172.
    PubMed     Text format     Abstract available


  198. ANTONARAKIS ES
    Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30167.
    PubMed     Text format    


  199. MONTIRONI R, Lopez-Beltran A, Cheng L, Gasparrini S, et al
    Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting
    Eur Urol. 2017 Mar 11. pii: S0302-2838(17)30127.
    PubMed     Text format    


  200. ICZKOWSKI KA
    Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2
    Eur Urol. 2017 Mar 8. pii: S0302-2838(17)30128.
    PubMed     Text format    


  201. MURPHY DG, Sweeney CJ, Tombal B
    "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer.
    Eur Urol. 2017 Mar 7. pii: S0302-2838(17)30131.
    PubMed     Text format     Abstract available


  202. ANNALA M, Struss WJ, Warner EW, Beja K, et al
    Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Eur Urol. 2017 Mar 1. pii: S0302-2838(17)30112.
    PubMed     Text format     Abstract available


  203. REIG O, Marin-Aguilera M, Carrera G, Jimenez N, et al
    Corrigendum re: "TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer" [Eur Urol 2016;70:709-13].
    Eur Urol. 2017 Mar 1. pii: S0302-2838(17)30116.
    PubMed     Text format    


  204. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Text format     Abstract available


  205. ADAM M, Tennstedt P, Lanwehr D, Tilki D, et al
    Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.
    Eur Urol. 2017;71:330-336.
    PubMed     Text format     Abstract available


  206. FOSSATI N, Wiklund P, Rochat CH, Montorsi F, et al
    Robotic and Open Radical Prostatectomy: The First Prospective Randomised Controlled Trial Fuels Debate Rather than Closing the Question.
    Eur Urol. 2017;71:307-308.
    PubMed     Text format     Abstract available


  207. DASKIVICH TJ, Spiegel B, Kim HL
    Online Ratings Systems for Physicians and Institutions: Limitations of the Current State of the Art.
    Eur Urol. 2017;71:311-312.
    PubMed     Text format     Abstract available


  208. BORGHESI M, Ahmed H, Nam R, Schaeffer E, et al
    Complications After Systematic, Random, and Image-guided Prostate Biopsy.
    Eur Urol. 2017;71:353-365.
    PubMed     Text format     Abstract available


  209. MUNGOVAN SF, Sandhu JS, Akin O, Smart NA, et al
    Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis.
    Eur Urol. 2017;71:368-378.
    PubMed     Text format     Abstract available


    February 2017
  210. VENDERINK W, van Luijtelaar A, Bomers JG, van der Leest M, et al
    Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
    Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110.
    PubMed     Text format     Abstract available


  211. TAAFFE DR, Newton RU, Spry N, Joseph D, et al
    Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
    Eur Urol. 2017 Feb 26. pii: S0302-2838(17)30108.
    PubMed     Text format     Abstract available


  212. KAPOOR J, Lamb AD, Murphy DG
    Re: Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Feb 23. pii: S0302-2838(17)30103.
    PubMed     Text format    


  213. MATEO J, Sharp A, de Bono JS
    Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30094.
    PubMed     Text format    


  214. JONES TA, Marks LS
    Re: A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30101.
    PubMed     Text format    


  215. SPRATT DE, Lee JY, Dess RT, Narayana V, et al
    Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30096.
    PubMed     Text format     Abstract available


  216. MOURACADE P
    Re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30085.
    PubMed     Text format    


  217. PRUTHI DK, Ankerst DP, Liss MA
    Novel Definitions of Low-risk and High-risk Prostate Cancer: Implications for the European Randomized Study of Screening for Prostate Cancer Risk Assessment Tool.
    Eur Urol. 2017 Feb 17. pii: S0302-2838(17)30098.
    PubMed     Text format    


  218. DAL MORO F, Motterle G, Barbieri L, Zattoni F, et al
    Re: Jean-Pierre Droz, Gilles Albrand, Silke Gillessen, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo
    Eur Urol. 2017 Feb 15. pii: S0302-2838(17)30088.
    PubMed     Text format    


  219. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Uro
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30086.
    PubMed     Text format    


  220. COZZARINI C, Benigni F, Fiorino C, Mondino A, et al
    Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisf
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30090.
    PubMed     Text format    


  221. VALE S
    Re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5: Precl
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30089.
    PubMed     Text format    


  222. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
    Eur Urol. 2017 Feb 11. pii: S0302-2838(17)30067.
    PubMed     Text format     Abstract available


  223. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
    Eur Urol. 2017 Feb 8. pii: S0302-2838(17)30068.
    PubMed     Text format    


  224. DOWNER MK, Allard CB, Preston MA, Gaziano JM, et al
    Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study.
    Eur Urol. 2017 Feb 8. pii: S0302-2838(17)30069.
    PubMed     Text format     Abstract available


  225. GANDAGLIA G, Briganti A, Clarke N, Karnes RJ, et al
    Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients.
    Eur Urol. 2017 Feb 8. pii: S0302-2838(17)30064.
    PubMed     Text format     Abstract available


  226. DU C, Chen H, Li C
    Re: Alessandro Morlacco, John C. Cheville, Laureano J. Rangel, Derek J. Gearman, R. Jeffrey Karnes. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-risk" Prostate Cancer: Implications for Active Surveillance. Eur Urol. In press
    Eur Urol. 2017 Feb 3. pii: S0302-2838(17)30065.
    PubMed     Text format    


  227. AHMAD AE, Finelli A
    Active Surveillance Discussion for Low-risk Prostate Cancer: Patients' Preferences and Counseling Techniques.
    Eur Urol. 2017 Feb 2. pii: S0302-2838(17)30060.
    PubMed     Text format    


  228. ROOBOL MJ, Verbeek JF, van der Kwast T, Kummerlin IP, et al
    Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Eur Urol. 2017 Feb 2. pii: S0302-2838(17)30058.
    PubMed     Text format     Abstract available


  229. SIVARAMAN A, Barret E
    Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluatio
    Eur Urol. 2017 Feb 1. pii: S0302-2838(17)30059.
    PubMed     Text format    


  230. GRANDE P, Di Pierro GB, Mordasini L, Ferrari M, et al
    Prospective Randomized Trial Comparing Titanium Clips to Bipolar Coagulation in Sealing Lymphatic Vessels During Pelvic Lymph Node Dissection at the Time of Robot-assisted Radical Prostatectomy.
    Eur Urol. 2017;71:155-158.
    PubMed     Text format     Abstract available


  231. MA TM, Tosoian JJ, Schaeffer EM, Landis P, et al
    The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Eur Urol. 2017;71:174-180.
    PubMed     Text format     Abstract available


  232. ALBERS P
    Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Eur Urol. 2017;71:300.
    PubMed     Text format    


  233. DAMSGAARD J, Joensen UN, Carlsen E, Erenpreiss J, et al
    Reply to Eugenio Ventimiglia, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Jakob Damsgaard, Ulla N. Joensen, Elisabeth Carlsen, et al. Varicocele Is Associated with Impaired Semen Quality and Reproductive Hormone Levels: A Study o
    Eur Urol. 2017;71:e71-e72.
    PubMed     Text format    


  234. STOLZENBURG JU, Kyriazis I, Liatsikos E
    Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach.
    Eur Urol. 2017;71:159-160.
    PubMed     Text format    


  235. PRADO K, Reiter RE
    Is Targeted Biopsy Applicable to Patients on Active Surveillance?
    Eur Urol. 2017;71:181-182.
    PubMed     Text format    


    January 2017
  236. MURPHY DG, Risbridger GP, Bristow RG, Sandhu S, et al
    The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer.
    Eur Urol. 2017 Jan 25. pii: S0302-2838(17)30043.
    PubMed     Text format    


  237. MICHEL MC
    Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Eur Urol. 2017 Jan 25. pii: S0302-2838(17)30047.
    PubMed     Text format    


  238. EHDAIE B, Assel M, Benfante N, Malhotra D, et al
    A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer.
    Eur Urol. 2017 Jan 24. pii: S0302-2838(17)30002.
    PubMed     Text format     Abstract available


  239. FOSSATI N, Willemse PM, van den Bergh RC, Van den Broeck T, et al
    The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
    Eur Urol. 2017 Jan 23. pii: S0302-2838(16)30900.
    PubMed     Text format     Abstract available


  240. EPSTEIN JI, Trock B, Han M
    Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason
    Eur Urol. 2017 Jan 17. pii: S0302-2838(17)30011.
    PubMed     Text format    


  241. FANKHAUSER CD, Mucci LA, Gerke TA
    Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.11.006.
    Eur Urol. 2017 Jan 17. pii: S0302-2838(17)30032.
    PubMed     Text format    


  242. KALLIDONIS P, Liatsikos E
    Re: Long-term Results of Active Surveillance in the Goteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Eur Urol. 2017 Jan 16. pii: S0302-2838(17)30014.
    PubMed     Text format    


  243. ZILLI T, Crehange G, Chapet O
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.
    Eur Urol. 2017 Jan 16. pii: S0302-2838(17)30016.
    PubMed     Text format    


  244. DE LAERE B, van Dam PJ, Whitington T, Mayrhofer M, et al
    Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    Eur Urol. 2017 Jan 16. pii: S0302-2838(17)30018.
    PubMed     Text format     Abstract available


  245. GIANNARINI G, Crestani A, Rossanese M, Ficarra V, et al
    Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold!
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30017.
    PubMed     Text format    


  246. MAY M, Stief CG, Brookman-May SD
    Re: The Role of Adjuvant Radiotherapy in Pathologically Lymph Node Positive Prostate Cancer.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30013.
    PubMed     Text format    


  247. RISCHMANN P
    Reply to Thomas Zilli, Gilles Crehange and Olivier Chapet's Letter to the Editor re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hem
    Eur Urol. 2017 Jan 11. pii: S0302-2838(17)30015.
    PubMed     Text format    


  248. DROZ JP, Albrand G, Gillessen S, Hughes S, et al
    Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
    Eur Urol. 2017 Jan 11. pii: S0302-2838(17)30001.
    PubMed     Text format     Abstract available


  249. LAMB AD, Lawrence MG, Sandhu S
    Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.
    Eur Urol. 2017 Jan 11. pii: S0302-2838(17)30004.
    PubMed     Text format    


  250. FODOR A, Fiorino C, Picchio M, Di Muzio N, et al
    Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.
    Eur Urol. 2017 Jan 5. pii: S0302-2838(16)30925.
    PubMed     Text format    


  251. MCLEOD DG, Srivastava S
    Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer.
    Eur Urol. 2017 Jan 5. pii: S0302-2838(16)30922.
    PubMed     Text format    


  252. SCHOUTEN MG, van der Leest M, Pokorny M, Hoogenboom M, et al
    Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naive Men?
    Eur Urol. 2017 Jan 4. pii: S0302-2838(16)30903.
    PubMed     Text format     Abstract available


  253. VALERIO M, Cerantola Y, Eggener SE, Lepor H, et al
    New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.
    Eur Urol. 2017;71:17-34.
    PubMed     Text format     Abstract available


  254. SPRATT DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, et al
    Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.
    Eur Urol. 2017;71:37-43.
    PubMed     Text format     Abstract available


  255. NICITA G, Villari D, Caroassai Grisanti S, Marzocco M, et al
    Minimally Invasive Transanal Repair of Rectourethral Fistulas.
    Eur Urol. 2017;71:133-138.
    PubMed     Text format     Abstract available


  256. LI Y, Donmez N, Sahinalp C, Xie N, et al
    SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Eur Urol. 2017;71:68-78.
    PubMed     Text format     Abstract available


    December 2016
  257. SUARDI N, Briganti A, Gandaglia G, Fossati N, et al
    Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?
    Eur Urol. 2016 Dec 30. pii: S0302-2838(16)30898.
    PubMed     Text format     Abstract available


  258. EPSTEIN JI
    Prostate Cancer Grade Groups Correlate with Prostate-specific Cancer Mortality: SEER Data for Contemporary Graded Specimens.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30918.
    PubMed     Text format    


  259. SCHIFF JP, Lewis BE, Ledet EM, Sartor O, et al
    Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30912.
    PubMed     Text format    


  260. GILD P, von Landenberg N, Cole AP
    Re: Phillip J. Gray, Chun Chieh Lin, Matthew R. Cooperberg, Ahmedin Jemal, Jason A. Efstathiou. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol. In press. http://dx.d
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30906.
    PubMed     Text format    


  261. BENTMAR HOLGERSSON M, Malm J, Lundberg Giwercman Y
    Serum Testosterone Levels in Early Prediction of Prostate Cancer Risk.
    Eur Urol. 2016 Dec 16. pii: S0302-2838(16)30896.
    PubMed     Text format    


  262. ANDERSON BB, Oberlin DT, Razmaria AA, Choy B, et al
    Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.
    Eur Urol. 2016 Dec 13. pii: S0302-2838(16)30880.
    PubMed     Text format     Abstract available


  263. SCHER HI, Graf RP, Schreiber NA, McLaughlin B, et al
    Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Dec 12. pii: S0302-2838(16)30857.
    PubMed     Text format     Abstract available


  264. NA R, Zheng SL, Han M, Yu H, et al
    Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Eur Urol. 2016 Dec 9. pii: S0302-2838(16)30885.
    PubMed     Text format     Abstract available


    November 2016
  265. PARKER WP, Karnes RJ, Mynderse LA, Lowe VJ, et al
    Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-spec
    Eur Urol. 2016 Nov 30. pii: S0302-2838(16)30855.
    PubMed     Text format    


  266. LIN DW, Newcomb LF, Brown MD, Sjoberg DD, et al
    Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Eur Urol. 2016 Nov 23. pii: S0302-2838(16)30850.
    PubMed     Text format     Abstract available


  267. TUTOLO M, Fossati N, Van der Aa F, Gandaglia G, et al
    Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management?
    Eur Urol. 2016 Nov 22. pii: S0302-2838(16)30811.
    PubMed     Text format    


  268. SUNDI D, Schaeffer EM
    Progress in Prognosis and Prediction for Men with Prostate Cancer.
    Eur Urol. 2016 Nov 22. pii: S0302-2838(16)30761.
    PubMed     Text format    


  269. HAM WS, Chalfin HJ, Feng Z, Trock BJ, et al
    New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Eur Urol. 2016 Nov 19. pii: S0302-2838(16)30806.
    PubMed     Text format     Abstract available


  270. WALLIS CJ, Satkunasivam R, Nam RK
    Postoperative Radiotherapy in Locally Advanced Prostate Cancer: A Question of Who and When.
    Eur Urol. 2016 Nov 17. pii: S0302-2838(16)30810.
    PubMed     Text format    


  271. KANABUR P, Scovell JM, Ramasamy R
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    Eur Urol. 2016 Nov 16. pii: S0302-2838(16)30808.
    PubMed     Text format    


  272. DE REIJKE TM, van Moorselaar JR
    Re: Ten-year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2016 Nov 15. pii: S0302-2838(16)30805.
    PubMed     Text format    


  273. DA SILVA FC, Oliveira P
    Tumor clone dynamics in lethal prostate cancer.
    Eur Urol. 2016 Nov 15. pii: S0302-2838(16)30800.
    PubMed     Text format    


  274. BOSSI A, Mottet N, Blanchard P
    Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time?
    Eur Urol. 2016 Nov 11. pii: S0302-2838(16)30793.
    PubMed     Text format    


  275. KANABUR P, Scovell JM, Ramasamy R
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    Eur Urol. 2016 Nov 9. pii: S0302-2838(16)30759.
    PubMed     Text format    


  276. YUAN R, Huang H
    Re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20.
    Eur Urol. 2016 Nov 8. pii: S0302-2838(16)30758.
    PubMed     Text format    


  277. COOPERBERG MR
    Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2016 Nov 3. pii: S0302-2838(16)30751.
    PubMed     Text format    


  278. TYSON MD, Alvarez J, Koyama T, Hoffman KE, et al
    Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study.
    Eur Urol. 2016 Nov 2. pii: S0302-2838(16)30750.
    PubMed     Text format     Abstract available


  279. VAN HEMELRIJCK M, Garmo H, Lindhagen L, Bratt O, et al
    Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
    Eur Urol. 2016 Nov 2. pii: S0302-2838(16)30745.
    PubMed     Text format     Abstract available


  280. COOPERBERG MR
    What Early ProtecT Results Have Confirmed About Risk-stratified Prostate Cancer Management.
    Eur Urol. 2016 Nov 1. pii: S0302-2838(16)30720.
    PubMed     Text format    


  281. SCHIAVINA R, Bianchi L, Borghesi M, Martorana G, et al
    Salvage Surgery for Nodal Recurrence of Prostate Cancer: Might the Robotic Approach Render an Experimental Procedure More Acceptable?
    Eur Urol. 2016 Nov 1. pii: S0302-2838(16)30747.
    PubMed     Text format    


  282. WILLIAMS SB, Chapin BF
    Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom?
    Eur Urol. 2016 Nov 1. pii: S0302-2838(16)30723.
    PubMed     Text format    


    October 2016
  283. BROOKMAN-MAY SD, May M, Lebentrau S, Klotz T, et al
    Re: Scott P. Kelly, Philip S. Rosenberg, William F. Anderson, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.05.011.
    Eur Urol. 2016 Oct 27. pii: S0302-2838(16)30727.
    PubMed     Text format    


  284. VIDAL AC, Freedland SJ
    Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30714.
    PubMed     Text format     Abstract available


  285. DE BONO J
    Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant
    Eur Urol. 2016 Oct 14. pii: S0302-2838(16)30699.
    PubMed     Text format    


  286. VAN SOEST RJ, de Wit R
    Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press.
    Eur Urol. 2016 Oct 13. pii: S0302-2838(16)30700.
    PubMed     Text format    


  287. STATTIN P, Bratt O
    Reply to Glen D. Santok and Koon H. Rha' Letter to the Editor re: Par Stattin, Fredrik Sandin, Frederik Birkebaek Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationw
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30677.
    PubMed     Text format    


  288. JOHNSTON TJ, Shaw GL, Lamb AD, Parashar D, et al
    Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30680.
    PubMed     Text format     Abstract available


  289. VILLA S, Kendel F, Venderbos L, Rancati T, et al
    Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30681.
    PubMed     Text format     Abstract available


  290. RISCHMANN P, Gelet A, Riche B, Villers A, et al
    Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30679.
    PubMed     Text format     Abstract available


  291. SYDES MR, Ritchie AW, James ND
    Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707-708.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30676.
    PubMed     Text format    


  292. SANTOK GD, Rha KH
    Re: Par Stattin, Fredrik Sandin, Frederik Birkebaek Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi
    Eur Urol. 2016 Oct 4. pii: S0302-2838(16)30678.
    PubMed     Text format    


    September 2016
  293. TEPLY BA, Kachhap S, Eisenberger MA, Denmeade SR, et al
    Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.
    Eur Urol. 2016 Sep 29. pii: S0302-2838(16)30642.
    PubMed     Text format    


  294. VILLERS A, Rubin MA
    Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30639.
    PubMed     Text format    


  295. MATTEI A, Grande P, Di Pierro GB
    Reply from Authors re: Jens Uwe Stolzenburg, Iason Kyriazis, Evangelos Liatsikos. Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Appr
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30658.
    PubMed     Text format    


  296. ROUVIERE O, Chapelon JY, Crouzet S, Gelet A, et al
    Prostate Cancer Focal Therapy: Just Because You Can Does Not Mean You Should.
    Eur Urol. 2016 Sep 21. pii: S0302-2838(16)30660.
    PubMed     Text format    


  297. CRONAUER MV, Merseburger AS, Hoda MR
    Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur
    Eur Urol. 2016 Sep 20. pii: S0302-2838(16)30643.
    PubMed     Text format    


  298. BERGDAHL AG, Wilderang U, Aus G, Carlsson S, et al
    Corrigendum re: "Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Goteborg Randomised Screening Trial" [Eur Urol 2016;70:566-73].
    Eur Urol. 2016 Sep 20. pii: S0302-2838(16)30636.
    PubMed     Text format    


  299. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Genera
    Eur Urol. 2016 Sep 16. pii: S0302-2838(16)30644.
    PubMed     Text format    


  300. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.08.038:
    Eur Urol. 2016 Sep 15. pii: S0302-2838(16)30583.
    PubMed     Text format    


  301. WIT EM, Acar C, Grivas N, Yuan C, et al
    Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy.
    Eur Urol. 2016 Sep 14. pii: S0302-2838(16)30617.
    PubMed     Text format     Abstract available


  302. DALELA D, Karabon P, Sammon J, Sood A, et al
    Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer.
    Eur Urol. 2016 Sep 13. pii: S0302-2838(16)30521.
    PubMed     Text format     Abstract available


  303. LIU P, Liu L, Zu X
    Re: Claude Schulman, Erik Cornel, Vsevolod Matveev, et al. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). Eur Urol 2016;69:720-7.
    Eur Urol. 2016 Sep 13. pii: S0302-2838(16)30579.
    PubMed     Text format    


  304. MAITLAND NJ
    Re: The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.
    Eur Urol. 2016 Sep 13. pii: S0302-2838(16)30574.
    PubMed     Text format    


  305. SANCHEZ-SALAS R
    Re: Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.
    Eur Urol. 2016 Sep 6. pii: S0302-2838(16)30576.
    PubMed     Text format    


  306. VENTIMIGLIA E, Salonia A, Briganti A, Montorsi F, et al
    Re: Family History and Probability of Prostate Cancer, Differentiated by Risk Category - A Nationwide Population-based Study.
    Eur Urol. 2016 Sep 5. pii: S0302-2838(16)30575.
    PubMed     Text format    


  307. COZZARINI C
    Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment?
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30525.
    PubMed     Text format    


  308. MONTORSI F, Gandaglia G, Fossati N, Suardi N, et al
    Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30524.
    PubMed     Text format     Abstract available


  309. ISAACS WB
    What Do Myeloma, Breast Cancer, and Prostate Cancer Have in Common?
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30531.
    PubMed     Text format    


  310. PARKER WP, Davis BJ, Park SS, Olivier KR, et al
    Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30528.
    PubMed     Text format     Abstract available


  311. GRAY PJ, Lin CC, Cooperberg MR, Jemal A, et al
    Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30520.
    PubMed     Text format     Abstract available


  312. JERECZEK-FOSSA BA
    Re: Stereotactic Body Re-irradiation Therapy for Locally Recurrent Prostate Cancer After External-beam Radiation Therapy: Initial Report.
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30532.
    PubMed     Text format    


  313. KIMURA T, Egawa S
    Re: Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30529.
    PubMed     Text format    


  314. PAPA N, Perera M, Hofman MS, Bolton D, et al
    Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emi
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30523.
    PubMed     Text format    


    August 2016
  315. ANTONARAKIS ES, Scher HI
    Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions.
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30505.
    PubMed     Text format    


  316. ZATTONI F, Zattoni F, Evangelista L
    Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30522.
    PubMed     Text format    


  317. SONPAVDE G, Antonarakis ES
    Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability.
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30526.
    PubMed     Text format    


  318. CORNFORD P, Bellmunt J, Bolla M, Briers E, et al
    EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30469.
    PubMed     Text format     Abstract available


  319. MATEO J, Boysen G, Barbieri CE, Bryant HE, et al
    DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    Eur Urol. 2016 Aug 30. pii: S0302-2838(16)30504.
    PubMed     Text format     Abstract available


  320. TRAN GN, Leapman MS, Nguyen HG, Cowan JE, et al
    Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
    Eur Urol. 2016 Aug 29. pii: S0302-2838(16)30490.
    PubMed     Text format     Abstract available


  321. BARENTSZ JO, Mulders P, Gerritsen W, Futterer JJ, et al
    Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging.
    Eur Urol. 2016 Aug 29. pii: S0302-2838(16)30513.
    PubMed     Text format    


  322. MORLACCO A, Sharma V, Viers BR, Rangel LJ, et al
    The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy.
    Eur Urol. 2016 Aug 28. pii: S0302-2838(16)30482.
    PubMed     Text format     Abstract available


  323. PORPIGLIA F, Manfredi M, Mele F, Cossu M, et al
    Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naive Patients with Suspected Prostate Cancer.
    Eur Urol. 2016 Aug 27. pii: S0302-2838(16)30509.
    PubMed     Text format     Abstract available


  324. MORLACCO A, Cheville JC, Rangel LJ, Gearman DJ, et al
    Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Eur Urol. 2016 Aug 27. pii: S0302-2838(16)30511.
    PubMed     Text format     Abstract available


  325. GANDAGLIA G, Fossati N, Stabile A, Bandini M, et al
    Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.
    Eur Urol. 2016 Aug 26. pii: S0302-2838(16)30508.
    PubMed     Text format     Abstract available


  326. DEL RE M, Biasco E, Crucitta S, Derosa L, et al
    The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Eur Urol. 2016 Aug 26. pii: S0302-2838(16)30479.
    PubMed     Text format     Abstract available


  327. MOTTET N, Bellmunt J, Bolla M, Briers E, et al
    EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2016 Aug 25. pii: S0302-2838(16)30470.
    PubMed     Text format     Abstract available


  328. PORRES D, Heidenreich A, Pfister D
    Re: Pattern of Progression After Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Eur Urol. 2016 Aug 24. pii: S0302-2838(16)30499.
    PubMed     Text format    


  329. MONTIRONI R, Gasparrini S, Mazzucchelli R, Massari F, et al
    Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.047.
    Eur Urol. 2016 Aug 24. pii: S0302-2838(16)30503.
    PubMed     Text format    


  330. KLIL-DRORI AJ, Azoulay L
    Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and Par Stattin's Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thro
    Eur Urol. 2016 Aug 23. pii: S0302-2838(16)30489.
    PubMed     Text format    


  331. HADASCHIK B
    Re: 225Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Aug 20. pii: S0302-2838(16)30495.
    PubMed     Text format    


  332. LAMB AD, Zargar H, Murphy DG, Corcoran NM, et al
    Disrupting the Status Quo in Prostate Cancer Diagnosis.
    Eur Urol. 2016 Aug 20. pii: S0302-2838(16)30485.
    PubMed     Text format    


  333. LOLKEMA M, Debets R, de Wit R
    Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?
    Eur Urol. 2016 Aug 17. pii: S0302-2838(16)30481.
    PubMed     Text format    


  334. VAN HEMELRIJCK M, Garmo H, Adolfsson J, Stattin P, et al
    Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol. 2016;70:56-61.
    Eur Urol. 2016 Aug 17. pii: S0302-2838(16)30488.
    PubMed     Text format    


  335. DE BONO JS
    Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastat
    Eur Urol. 2016 Aug 17. pii: S0302-2838(16)30478.
    PubMed     Text format    


  336. ROVIELLO G, Generali D, Petrioli R
    Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press.
    Eur Urol. 2016 Aug 16. pii: S0302-2838(16)30477.
    PubMed     Text format    


  337. COLEY RY, Zeger SL, Mamawala M, Pienta KJ, et al
    Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
    Eur Urol. 2016 Aug 11. pii: S0302-2838(16)30472.
    PubMed     Text format     Abstract available


  338. VOGELZANG NJ, Fizazi K, Burke JM, De Wit R, et al
    Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Aug 10. pii: S0302-2838(16)30467.
    PubMed     Text format     Abstract available


  339. MORTEZAVI A, Eberli D
    Re: Prostate Cancer Detection with Magnetic Resonance-ultrasound Fusion Biopsy: The Role of Systematic and Targeted Biopsies.
    Eur Urol. 2016 Aug 5. pii: S0302-2838(16)30455.
    PubMed     Text format    


  340. FRANK C, Sundquist J, Hemminki A, Hemminki K, et al
    Familial Associations Between Prostate Cancer and Other Cancers.
    Eur Urol. 2016 Aug 4. pii: S0302-2838(16)30436.
    PubMed     Text format     Abstract available


  341. HEIDENREICH A, Chowdhury S, Klotz L, Siemens DR, et al
    Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
    Eur Urol. 2016 Aug 3. pii: S0302-2838(16)30432.
    PubMed     Text format     Abstract available


  342. YLITALO EB, Thysell E, Jernberg E, Lundholm M, et al
    Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
    Eur Urol. 2016 Aug 3. pii: S0302-2838(16)30438.
    PubMed     Text format     Abstract available


  343. GOVOROV A
    Re: More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat Versus Initial Transrectal Ultrasound Guided Prostate Biopsy.
    Eur Urol. 2016 Aug 2. pii: S0302-2838(16)30443.
    PubMed     Text format    


  344. MOSCHINI M, Shariat SF
    Re: Failure-Free Survival and Radiotherapy in Patients with Newly Diagnosed Nonmetastatic Prostate Cancer: Data from Patients in the Control Arm of the STAMPEDE Trial.
    Eur Urol. 2016;70:398-9.
    PubMed     Text format    


    July 2016
  345. FOSSATI N, Karnes RJ, Boorjian SA, Moschini M, et al
    Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Eur Urol. 2016 Jul 30. pii: S0302-2838(16)30433.
    PubMed     Text format     Abstract available


  346. LAZZERI M, Lughezzani G
    Re: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30444.
    PubMed     Text format    


  347. BJARTELL AS
    Re: The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30442.
    PubMed     Text format    


  348. LUDWIG WW, Ross AE, Pierorazio PM
    Local Therapy for Gleason 9-10 Prostate Cancer: Looking to the Future.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30430.
    PubMed     Text format    


  349. STATTIN P, Sandin F, Thomsen FB, Garmo H, et al
    Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30428.
    PubMed     Text format     Abstract available


  350. EIBER M, Herrmann K, Fendler WP, Maurer T, et al
    68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30450.
    PubMed     Text format    


  351. BEER TM, Armstrong AJ, Rathkopf D, Loriot Y, et al
    Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
    Eur Urol. 2016 Jul 28. pii: S0302-2838(16)30437.
    PubMed     Text format     Abstract available


  352. KELLY SP, Rosenberg PS, Anderson WF, Andreotti G, et al
    Trends in the Incidence of Fatal Prostate Cancer in the United States by Race.
    Eur Urol. 2016 Jul 27. pii: S0302-2838(16)30175.
    PubMed     Text format     Abstract available


  353. BERNEMANN C, Schnoeller TJ, Luedeke M, Steinestel K, et al
    Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Eur Urol. 2016 Jul 25. pii: S0302-2838(16)30426.
    PubMed     Text format     Abstract available


  354. BAYNE CE, Williams SB, Chapin BF
    Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Uro
    Eur Urol. 2016 Jul 23. pii: S0302-2838(16)30421.
    PubMed     Text format    


  355. EGEVAD L, Samaratunga H, Srigley JR, Delahunt B, et al
    Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1.
    Eur Urol. 2016 Jul 22. pii: S0302-2838(16)30424.
    PubMed     Text format    


  356. WHITE NM, Zhao SG, Zhang J, Rozycki EB, et al
    Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer.
    Eur Urol. 2016 Jul 22. pii: S0302-2838(16)30417.
    PubMed     Text format     Abstract available


  357. ZIETMAN A, Smith J, Klein E, Droller M, et al
    Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of
    Eur Urol. 2016 Jul 21. pii: S0302-2838(16)30425.
    PubMed     Text format    


  358. WEI L, Wang J, Lampert E, Schlanger S, et al
    Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
    Eur Urol. 2016 Jul 20. pii: S0302-2838(16)30406.
    PubMed     Text format     Abstract available


  359. YANG L, Qiu S, Wei Q
    Re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.
    Eur Urol. 2016 Jul 20. pii: S0302-2838(16)30423.
    PubMed     Text format    


  360. GILLESSEN S, Gilson C, James N, Adler A, et al
    Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
    Eur Urol. 2016 Jul 19. pii: S0302-2838(16)30420.
    PubMed     Text format     Abstract available


  361. TSAO CK, Galsky MD, Oh WK
    Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30393.
    PubMed     Text format     Abstract available


  362. GETTMAN MT
    Thoughts on Criteria for Active Surveillance of Favorable-risk Prostate Cancer.
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30384.
    PubMed     Text format    


  363. CULIG Z
    STAT3 in Prostate Cancer: Whom Should We Treat and When?
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30386.
    PubMed     Text format    


  364. HU JC, Nanus DM, Sedrakyan A
    Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States.
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30388.
    PubMed     Text format    


  365. DE BONO JS, Smith MR, Saad F, Rathkopf DE, et al
    Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30385.
    PubMed     Text format     Abstract available


  366. CHANG X, Chao Z, Zheng-Yan G
    Re: Alison J. Price, Ruth C. Travis, Paul N. Appleby, et al. Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. Eur Urol. In
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30340.
    PubMed     Text format    


  367. LANGE PH
    Re: Intermittent Androgen Deprivation (IAD) in Prostate Cancer (PC): Are We Ready To Quit?
    Eur Urol. 2016 Jul 4. pii: S0302-2838(16)30346.
    PubMed     Text format    


  368. KLIMENT J
    Re: Predicting Prostate Cancer-specific Outcome After Radical Prostatectomy Among Men with Very High-risk cT3b/4 PCa: A Multi-institutional Outcome Study of 266 Patients.
    Eur Urol. 2016 Jul 4. pii: S0302-2838(16)30348.
    PubMed     Text format    


  369. LAMOUREUX F, Thomas C, Yin MJ, Fazli L, et al
    Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55].
    Eur Urol. 2016;70:e27-e28.
    PubMed     Text format    


  370. PEARD L, Falkenstrom A, Klaassen Z, Terris MK, et al
    Re: Mental Health Outcomes in Elderly Men with Prostate Cancer.
    Eur Urol. 2016;70:206-7.
    PubMed     Text format    


  371. LUCCA I, Shariat SF
    Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Eur Urol. 2016;70:205-6.
    PubMed     Text format    


  372. WITJES WP
    Re: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer.
    Eur Urol. 2016;70:204-5.
    PubMed     Text format    


  373. DONALDSON JF, McNeill SA
    Re: Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Eur Urol. 2016 Jul 1. pii: S0302-2838(16)30345.
    PubMed     Text format    


    June 2016
  374. PERERA M, Papa N, Christidis D, Wetherell D, et al
    Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2016 Jun 27. pii: S0302-2838(16)30293.
    PubMed     Text format     Abstract available


  375. MOORE CM, Giganti F, Albertsen P, Allen C, et al
    Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.
    Eur Urol. 2016 Jun 24. pii: S0302-2838(16)30281.
    PubMed     Text format     Abstract available


  376. PARKER C, Finkelstein SE, Michalski JM, O'Sullivan JM, et al
    Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Eur Urol. 2016 Jun 22. pii: S0302-2838(16)30272.
    PubMed     Text format     Abstract available


  377. DON-DONCOW N, Marginean F, Coleman I, Nelson PS, et al
    Expression of STAT3 in Prostate Cancer Metastases.
    Eur Urol. 2016 Jun 22. pii: S0302-2838(16)30288.
    PubMed     Text format     Abstract available


  378. NEAL D, Lilja H
    Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer.
    Eur Urol. 2016 Jun 22. pii: S0302-2838(16)30284.
    PubMed     Text format    


  379. SAITO K
    Local Treatment of the Prostate in Metastatic Prostate Cancer: Need to Change the Concept?
    Eur Urol. 2016 Jun 20. pii: S0302-2838(16)30278.
    PubMed     Text format    


  380. PADHANI AR, Lecouvet FE, Tunariu N, Koh DM, et al
    METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.
    Eur Urol. 2016 Jun 14. pii: S0302-2838(16)30241.
    PubMed     Text format     Abstract available


  381. RIDER JR, Wilson KM, Mucci LA, Giovannucci EL, et al
    Reply to Cedric Annweiler, Pierre Bigot, and Spyridon N. Karras' Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate
    Eur Urol. 2016 Jun 14. pii: S0302-2838(16)30263.
    PubMed     Text format    


  382. TOSOIAN JJ, Trock BJ, Ballentine Carter H, Mamawala M, et al
    Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Imm
    Eur Urol. 2016 Jun 13. pii: S0302-2838(16)30245.
    PubMed     Text format    


  383. WONG MC, Goggins WB, Wang HH, Fung FD, et al
    Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries.
    Eur Urol. 2016 Jun 8. pii: S0302-2838(16)30251.
    PubMed     Text format     Abstract available


  384. LORENTE D, Olmos D, Mateo J, Bianchini D, et al
    Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
    Eur Urol. 2016 Jun 8. pii: S0302-2838(16)30187.
    PubMed     Text format     Abstract available


  385. LOEB S, Curnyn C, Sedlander E
    Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.
    Eur Urol. 2016 Jun 6. pii: S0302-2838(16)30247.
    PubMed     Text format    


  386. ANNWEILER C, Bigot P, Karras SN
    Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. In press. ht
    Eur Urol. 2016 Jun 4. pii: S0302-2838(16)30252.
    PubMed     Text format    


  387. YAN W, Zhou Z, Li H
    Re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
    Eur Urol. 2016 Jun 1. pii: S0302-2838(16)30244.
    PubMed     Text format    


  388. BRATT O
    Re: Risk of Malignant Melanoma in Men with Prostate Cancer. Nationwide, Population-based Cohort Study.
    Eur Urol. 2016;69:1158-9.
    PubMed     Text format    


  389. SCHLOMM T
    Re: The Molecular Taxonomy of Primary Prostate Cancer.
    Eur Urol. 2016;69:1157.
    PubMed     Text format    


  390. STERNBERG CN
    Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
    Eur Urol. 2016;69:1155-6.
    PubMed     Text format    


    May 2016
  391. STERNBERG CN
    Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?
    Eur Urol. 2016 May 30. pii: S0302-2838(16)30199.
    PubMed     Text format    


  392. CONTEDUCA V, Lolli C, De Giorgi U
    Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In p
    Eur Urol. 2016 May 30. pii: S0302-2838(16)30197.
    PubMed     Text format    


  393. RESCIGNO P, de Bono JS
    Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Sur
    Eur Urol. 2016 May 27. pii: S0302-2838(16)30198.
    PubMed     Text format    


  394. GEYNISMAN DM, Plimack ER, Zibelman M
    Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?
    Eur Urol. 2016 May 26. pii: S0302-2838(16)30190.
    PubMed     Text format    


  395. OBEID R, Pietrzik K
    Re: Alison J. Price, Ruth C. Travis, Paul N. Appleby, et al. Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. Eur Urol. In pr
    Eur Urol. 2016 May 25. pii: S0302-2838(16)30188.
    PubMed     Text format    


  396. WAUGH DJ
    Expanding the Armamentarium for Castrate-resistant Prostate Cancer.
    Eur Urol. 2016 May 24. pii: S0302-2838(16)30186.
    PubMed     Text format    


  397. GARDINER RA, Mainwaring P, Lavin MF
    Integrating Molecular Profiling of Liquid Biopsy Samples with a Calculator Algorithm To Detect High-risk Prostate Cancer.
    Eur Urol. 2016 May 24. pii: S0302-2838(16)30176.
    PubMed     Text format    


  398. GODTMAN RA, Stranne J, Hugosson J
    Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.04.024.
    Eur Urol. 2016 May 19. pii: S0302-2838(16)30159.
    PubMed     Text format    


  399. PAKARAINEN T, Raitanen J, Talala K, Taari K, et al
    Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Eur Urol. 2016 May 19. pii: S0302-2838(16)30173.
    PubMed     Text format     Abstract available


  400. ALONGI F, Mazzola R, Fersino S
    Re: Patrick C. Walsh, Nathan Lawrentschuk. Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. Eur Urol 2016;69:191-2: Personalization of
    Eur Urol. 2016 May 18. pii: S0302-2838(16)30178.
    PubMed     Text format    


  401. FIZAZI K, De Porre P, Londhe A, McGowan T, et al
    Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone
    Eur Urol. 2016 May 18. pii: S0302-2838(16)30158.
    PubMed     Text format    


  402. GANDAGLIA G, De Lorenzis E, Novara G, Fossati N, et al
    Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
    Eur Urol. 2016 May 18. pii: S0302-2838(16)30172.
    PubMed     Text format     Abstract available


  403. FRANCINI E, Sweeney CJ
    Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 May 13. pii: S0302-2838(16)30155.
    PubMed     Text format     Abstract available


  404. LOPPENBERG B, Dalela D, Karabon P, Sood A, et al
    The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
    Eur Urol. 2016 May 9. pii: S0302-2838(16)30141.
    PubMed     Text format     Abstract available


  405. SMITH MR, Antonarakis ES, Ryan CJ, Berry WR, et al
    Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
    Eur Urol. 2016 May 5. pii: S0302-2838(16)30133.
    PubMed     Text format     Abstract available


  406. SAEED K, Rahkama V, Eldfors S, Bychkov D, et al
    Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
    Eur Urol. 2016 May 5. pii: S0302-2838(16)30080.
    PubMed     Text format     Abstract available


  407. RIDER JR, Wilson KM, Sinnott JA, Kelly RS, et al
    Reply to Herney Andres Garcia-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate C
    Eur Urol. 2016 May 4. pii: S0302-2838(16)30142.
    PubMed     Text format    


  408. GARCIA-PERDOMO HA, Manzano Nunez R
    Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. In press. htt
    Eur Urol. 2016 May 4. pii: S0302-2838(16)30140.
    PubMed     Text format    


  409. LEAPMAN MS, Ameli N, Cooperberg MR, Chu C, et al
    Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance.
    Eur Urol. 2016 May 3. pii: S0302-2838(16)30131.
    PubMed     Text format     Abstract available


  410. KEARNS JT
    Corrigendum re: "Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer" [Eur Urol 2016;69:223-8].
    Eur Urol. 2016 May 2. pii: S0302-2838(16)30130.
    PubMed     Text format    


  411. VAN DEN BERGH RC, Murphy DG, van der Poel HG
    Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future.
    Eur Urol. 2016 May 2. pii: S0302-2838(16)30134.
    PubMed     Text format    


  412. DELL'OGLIO P, Suardi N
    Re: Acute Toxicity and Quality of Life After Dose-intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
    Eur Urol. 2016;69:966.
    PubMed     Text format    


  413. SIMONE G, Anceschi U, Gallucci M
    Re: Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: A Prospective Development Study.
    Eur Urol. 2016;69:965-6.
    PubMed     Text format    


  414. VAN DEN BERGH RC, Zargar H, Murphy DG
    Re: Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    Eur Urol. 2016;69:964-5.
    PubMed     Text format    


    April 2016
  415. RUD E, Baco E
    Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40: Is Contrast-enhanced Magnetic Resonance Imaging Really Necessary When Searching for Prost
    Eur Urol. 2016 Apr 25. pii: S0302-2838(16)30076.
    PubMed     Text format    


  416. NEWTON RU, Galvao DA
    Accumulating Evidence for Physical Activity and Prostate Cancer Survival: Time for a Definitive Trial of Exercise Medicine?
    Eur Urol. 2016 Apr 23. pii: S0302-2838(16)30077.
    PubMed     Text format    


  417. WELTI J, Rodrigues DN, Sharp A, Sun S, et al
    Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Apr 22. pii: S0302-2838(16)30027.
    PubMed     Text format     Abstract available


  418. VAN NESTE L, Hendriks RJ, Dijkstra S, Trooskens G, et al
    Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Eur Urol. 2016 Apr 20. pii: S0302-2838(16)30071.
    PubMed     Text format     Abstract available


  419. GULATI R, Etzioni R
    A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden.
    Eur Urol. 2016 Apr 15. pii: S0302-2838(16)30065.
    PubMed     Text format    


  420. GODTMAN RA, Holmberg E, Khatami A, Pihl CG, et al
    Long-term Results of Active Surveillance in the Goteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Eur Urol. 2016 Apr 15. pii: S0302-2838(16)30026.
    PubMed     Text format     Abstract available


  421. LOEB S
    Will Changes to Prostate Cancer Screening Guidelines Preserve Benefits and Reduce Harm?
    Eur Urol. 2016 Apr 15. pii: S0302-2838(16)30025.
    PubMed     Text format    


  422. LI H, Yan W, Ji Z
    Re: Hashim U. Ahmed, Louise Dickinson, Susan Charman, et al. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. Eur Urol 2015;68:927-36.
    Eur Urol. 2016 Apr 13. pii: S0302-2838(16)30028.
    PubMed     Text format    


  423. CARLSSON S, Assel M, Ulmert D, Gerdtsson A, et al
    Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Eur Urol. 2016 Apr 12. pii: S0302-2838(16)00376.
    PubMed     Text format     Abstract available


  424. PRICE AJ, Travis RC, Appleby PN, Albanes D, et al
    Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls.
    Eur Urol. 2016 Apr 6. pii: S0302-2838(16)00379.
    PubMed     Text format     Abstract available


  425. WALZ J
    Re: Comparison of MR/Ultrasound Fusion-Guided Biopsy With Ultrasound-guided Biopsy for the Diagnosis of Prostate Cancer.
    Eur Urol. 2016;69:756-7.
    PubMed     Text format    


  426. MATHIEU R, Shariat SF
    Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Eur Urol. 2016;69:755-6.
    PubMed     Text format    


  427. KIMURA T, Egawa S
    Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
    Eur Urol. 2016;69:754-5.
    PubMed     Text format    


  428. LARCHER A, Fossati N, Dell'Oglio P, Montorsi F, et al
    Reply from Authors re: Matthew C. Hayes, David J. Breen. Excision Versus Ablation in Renal Cancer: Optimising Outcome and Minimising Risk. Eur Urol 2016;69:683-4.
    Eur Urol. 2016;69:684-5.
    PubMed     Text format    


  429. ALBERTSEN PC
    Another Reason to Consider Active Surveillance.
    Eur Urol. 2016;69:582-3.
    PubMed     Text format    


  430. DAL PRA A, Spahn M
    Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Po
    Eur Urol. 2016;69:e74-5.
    PubMed     Text format    


  431. HAMILTON ZA, Kane CJ
    Nerve-sparing Technique During Radical Prostatectomy and its Effect on Urinary Continence.
    Eur Urol. 2016;69:590-1.
    PubMed     Text format    


    March 2016
  432. RIDER JR, Wilson KM, Sinnott JA, Kelly RS, et al
    Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.
    Eur Urol. 2016 Mar 28. pii: S0302-2838(16)00377.
    PubMed     Text format     Abstract available


  433. EVANGELISTA L, Fanti S, Picchio M
    Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for F/C-choline, New Tracers for Positron Emission Tomography and a Promising Hybri
    Eur Urol. 2016 Mar 26. pii: S0302-2838(16)00374.
    PubMed     Text format    


  434. FOSSA SD, Wiklund F, Klepp O, Angelsen A, et al
    Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandina
    Eur Urol. 2016 Mar 26. pii: S0302-2838(16)00278.
    PubMed     Text format     Abstract available


  435. LOPCI E, Chiti A, Lazzeri M
    Re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for F/C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur
    Eur Urol. 2016 Mar 25. pii: S0302-2838(16)00375.
    PubMed     Text format    


  436. VAN STAM MA, Aaronson NK, Pos FJ, Bosch JL, et al
    The Effect of Salvage Radiotherapy and its Timing on the Health-related Quality of Life of Prostate Cancer Patients.
    Eur Urol. 2016 Mar 22. pii: S0302-2838(16)00267.
    PubMed     Text format     Abstract available


  437. ZIETMAN A, Smith J, Klein E, Droller M, et al
    Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required.
    Eur Urol. 2016 Mar 21. pii: S0302-2838(16)00264.
    PubMed     Text format    


  438. EVANS CP, Higano CS, Keane T, Andriole G, et al
    The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Mar 19. pii: S0302-2838(16)00274.
    PubMed     Text format     Abstract available


  439. SHOAG J, Mittal S, Halpern JA, Scherr D, et al
    Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Eur Urol. 2016 Mar 17. pii: S0302-2838(16)00060.
    PubMed     Text format     Abstract available


  440. FOSSATI N, Gandaglia G, Bossi A, Montorsi F, et al
    Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2
    Eur Urol. 2016 Mar 15. pii: S0302-2838(16)00269.
    PubMed     Text format    


  441. FIZAZI K, Chi KN, de Bono JS, Gomella LG, et al
    Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Mar 7. pii: S0302-2838(16)00213.
    PubMed     Text format     Abstract available


  442. RESCIGNO P, Lorente D, Bianchini D, Ferraldeschi R, et al
    Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Mar 7. pii: S0302-2838(16)00245.
    PubMed     Text format     Abstract available


  443. TOUIJER KA, Eastham JA
    The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer.
    Eur Urol. 2016 Mar 5. pii: S0302-2838(16)00237.
    PubMed     Text format    


  444. DICKINSON L, Arya M, Afzal N, Cathcart P, et al
    Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
    Eur Urol. 2016 Mar 4. pii: S0302-2838(16)00244.
    PubMed     Text format     Abstract available


  445. MURPHY DG, Zargar H
    Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Eur Urol. 2016;69:540.
    PubMed     Text format    


  446. CHAN J, Roach M
    Words of Wisdom. Re: Genomic Classifier Identifies Men with Adverse Pathology After Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy.
    Eur Urol. 2016;69:539-40.
    PubMed     Text format    


  447. AHMAD AE, Finelli A
    Should Prebiopsy Multiparametric Magnetic Resonance Imaging be Offered to All Biopsy-naive Men Undergoing Prostate Biopsy?
    Eur Urol. 2016;69:426-7.
    PubMed     Text format    


  448. PORPIGLIA F, Bertolo R, Manfredi M, De Luca S, et al
    Total Anatomical Reconstruction During Robot-assisted Radical Prostatectomy: Implications on Early Recovery of Urinary Continence.
    Eur Urol. 2016;69:485-95.
    PubMed     Text format     Abstract available


  449. MENG X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, et al
    Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Eur Urol. 2016;69:512-7.
    PubMed     Text format     Abstract available


  450. GIANNARINI G, Briganti A, Crestani A, Rossanese M, et al
    Dismiss Systematic Transrectal Ultrasound-guided and Embrace Targeted Magnetic Resonance Imaging-informed Prostate Biopsy: Is the Paradigm Ready to Shift?
    Eur Urol. 2016;69:381-3.
    PubMed     Text format    


  451. BRAUN K, Sjoberg DD, Vickers AJ, Lilja H, et al
    A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Eur Urol. 2016;69:505-11.
    PubMed     Text format     Abstract available


  452. ROSS AE, Yousefi K, Davicioni E, Ghadessi M, et al
    Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
    Eur Urol. 2016;69:496-504.
    PubMed     Text format     Abstract available


    February 2016
  453. BARBOSA PV, Thomas IC, Srinivas S, Buyyounouski MK, et al
    Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
    Eur Urol. 2016 Feb 29. pii: S0302-2838(16)00215.
    PubMed     Text format     Abstract available


  454. TREE AC, van As NJ, Dearnaley DP
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 29. pii: S0302-2838(16)00222.
    PubMed     Text format    


  455. REIG O, Marin-Aguilera M, Carrera G, Jimenez N, et al
    TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Feb 29. pii: S0302-2838(16)00212.
    PubMed     Text format     Abstract available


  456. LAZAR AA, Lizarraga TL, Roach M 3rd
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010: Radical Pr
    Eur Urol. 2016 Feb 27. pii: S0302-2838(16)00220.
    PubMed     Text format    


  457. FROEHNER M, Wirth MP
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 27. pii: S0302-2838(16)00221.
    PubMed     Text format    


  458. OST P, Ghadjar P
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 26. pii: S0302-2838(16)00219.
    PubMed     Text format    


  459. PARKER C
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 26. pii: S0302-2838(16)00217.
    PubMed     Text format    


  460. WALLIS CJ, Nam RK
    Reply from Authors re: Martin Spahn, Alan Dal Pra, Daniel Aebersold, Bertrand Tombal. Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.01.049: Prostate Cancer Treatm
    Eur Urol. 2016 Feb 25. pii: S0302-2838(16)00216.
    PubMed     Text format    


  461. BLANCHARD P, Briganti A, Bossi A
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 24. pii: S0302-2838(16)00218.
    PubMed     Text format    


  462. GANDAGLIA G, Briganti A, Fossati N, Salonia A, et al
    The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
    Eur Urol. 2016 Feb 22. pii: S0302-2838(16)00210.
    PubMed     Text format     Abstract available


  463. MARTIN NE, Stowell C
    Reply to Daniela Wittmann, Ted A. Skolarus' Letter to the Editor re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2014;67:460-7.
    Eur Urol. 2016 Feb 9. pii: S0302-2838(16)00160.
    PubMed     Text format    


  464. WITTMANN D, Skolarus TA
    Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2015;67:460-7.
    Eur Urol. 2016 Feb 9. pii: S0302-2838(16)00161.
    PubMed     Text format    


  465. THOMPSON IM JR, Ankerst DP
    The Role of Magnetic Resonance Imaging in Prostate Cancer: Focusing on What Really Matters.
    Eur Urol. 2016 Feb 6. pii: S0302-2838(16)00158.
    PubMed     Text format    


  466. NGUYEN DP, Huber PM, Metzger TA, Genitsch V, et al
    A Specific Mapping Study Using Fluorescence Sentinel Lymph Node Detection in Patients with Intermediate- and High-risk Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection.
    Eur Urol. 2016 Feb 4. pii: S0302-2838(16)00136.
    PubMed     Text format     Abstract available


  467. TAGAWA ST, Posadas EM, Bruce J, Lim EA, et al
    Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Feb 3. pii: S0302-2838(16)00130.
    PubMed     Text format     Abstract available


  468. EVANGELISTA L, Briganti A, Fanti S, Joniau S, et al
    New Clinical Indications for F/C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Eur Urol. 2016 Feb 2. pii: S0302-2838(16)00131.
    PubMed     Text format     Abstract available


  469. ISBARN H
    Re: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer.
    Eur Urol. 2016;69:372-3.
    PubMed     Text format    


  470. GANDAGLIA G, Briganti A, Montorsi F
    Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer.
    Eur Urol. 2016;69:370.
    PubMed     Text format    


  471. BESSEDE T, Patard JJ
    Words of Wisdom. Re: The Use of Early Postoperative Prostate-specific Antigen to Stratify Risk in Patients with Positive Surgical Margins After Radical Prostatectomy.
    Eur Urol. 2016;69:372.
    PubMed     Text format    


  472. COOPER CS, Clark J, Brewer DS, Edwards DR, et al
    Prostate Single Nucleotide Polymorphism Provides a Crucial Clue to Cancer Aggression in Active Surveillance Patients.
    Eur Urol. 2016;69:229-30.
    PubMed     Text format    


  473. WALSH PC, Lawrentschuk N
    Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins.
    Eur Urol. 2016;69:191-2.
    PubMed     Text format     Abstract available


  474. SHIN T, Ukimura O, Gill IS
    Three-dimensional Printed Model of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Nerve-sparing Prostatectomy.
    Eur Urol. 2016;69:377-9.
    PubMed     Text format    


  475. MOSCHINI M, Briganti A, Murphy CR, Bianchi M, et al
    Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy.
    Eur Urol. 2016;69:193-6.
    PubMed     Text format     Abstract available


    January 2016
  476. PISANSKY TM
    Salvage Radiotherapy for Postoperative Biochemical Failure of Prostate Cancer: The Path Toward Personalized Medicine.
    Eur Urol. 2016 Jan 29. pii: S0302-2838(16)00135.
    PubMed     Text format    


  477. FABRIS L, Ceder Y, Chinnaiyan AM, Jenster GW, et al
    The Potential of MicroRNAs as Prostate Cancer Biomarkers.
    Eur Urol. 2016 Jan 21. pii: S0302-2838(16)00012.
    PubMed     Text format     Abstract available


  478. LEPOR H
    The Challenge for Urologists Is to Screen, Detect, and Treat Prostate Cancer "Smarter": Will Ablative Technology Result in Smarter Treatment?
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00075.
    PubMed     Text format    


  479. HERLEMANN A, Wenter V, Kretschmer A, Thierfelder KM, et al
    Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
    Eur Urol. 2016 Jan 19. pii: S0302-2838(16)00009.
    PubMed     Text format     Abstract available


  480. EIBER M, Weirich G, Holzapfel K, Souvatzoglou M, et al
    Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.
    Eur Urol. 2016 Jan 18. pii: S0302-2838(16)00011.
    PubMed     Text format     Abstract available


  481. YOSHIMURA K, Minami T, Nozawa M, Kimura T, et al
    A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Jan 15. pii: S0302-2838(16)00008.
    PubMed     Text format     Abstract available


  482. CARAM ME, Skolarus TA, Cooney KA
    Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis.
    Eur Urol. 2016 Jan 14. pii: S0302-2838(15)01265.
    PubMed     Text format     Abstract available


  483. FRIEDENREICH CM, Wang Q, Neilson HK, Kopciuk KA, et al
    Physical Activity and Survival After Prostate Cancer.
    Eur Urol. 2016 Jan 7. pii: S0302-2838(15)01241.
    PubMed     Text format     Abstract available


  484. CHIN JL, Billia M, Relle J, Roethke MC, et al
    Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Eur Urol. 2016 Jan 6. pii: S0302-2838(15)01238.
    PubMed     Text format     Abstract available


  485. SIVARAMAN A, Barret E
    Focal Therapy for Prostate Cancer: An "A la Carte" Approach.
    Eur Urol. 2016 Jan 5. pii: S0302-2838(15)01223.
    PubMed     Text format     Abstract available


  486. DE REIJKE T
    Words of Wisdom: Re: Chemohormonal Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2016;69:178.
    PubMed     Text format    


  487. PINTHUS J, Morris C
    Words or Wisdom: Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer.
    Eur Urol. 2016;69:177-8.
    PubMed     Text format    


  488. LAZZERI M, Guazzoni G
    Words of Wisdom: Re: Shift Work and Prostate Cancer Incidence in Industrial Workers: A Historical Cohort Study in a German Chemical Company.
    Eur Urol. 2016;69:175-6.
    PubMed     Text format    


  489. THOMAS JA, Bachmann A
    Reply from Authors re: Jean-Nicolas Cornu, Stephan Madersbacher. Greenlight Photovaporisation of the Prostate: Now Ready for Prime Time. Eur Urol 2016;69:103-4.
    Eur Urol. 2016;69:105-6.
    PubMed     Text format    


  490. CHEN RC
    Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy.
    Eur Urol. 2016;69:58-9.
    PubMed     Text format    


    December 2015
  491. GREY A
    Osteoporosis and Fracture Risk in Men with Prostate Cancer.
    Eur Urol. 2015 Dec 31. pii: S0302-2838(15)01256.
    PubMed     Text format    


  492. BIANCHI L, Nini A, Bianchi M, Gandaglia G, et al
    The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Eur Urol. 2015 Dec 31. pii: S0302-2838(15)01218.
    PubMed     Text format     Abstract available


  493. LOEB S, Folkvaljon Y, Robinson D, Schlomm T, et al
    Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Eur Urol. 2015 Dec 29. pii: S0302-2838(15)01221.
    PubMed     Text format     Abstract available


  494. GRENABO BERGDAHL A, Wilderang U, Aus G, Carlsson S, et al
    Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Goteborg Randomised Screening Trial.
    Eur Urol. 2015 Dec 24. pii: S0302-2838(15)01214.
    PubMed     Text format     Abstract available


  495. CHENG HH, Pritchard CC, Boyd T, Nelson PS, et al
    Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2015 Dec 23. pii: S0302-2838(15)01177.
    PubMed     Text format     Abstract available


  496. MEHRA R, Udager AM, Ahearn TU, Cao X, et al
    Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
    Eur Urol. 2015 Dec 23. pii: S0302-2838(15)01211.
    PubMed     Text format     Abstract available


  497. KAPLAN AL, Hu JC, Morgentaler A, Mulhall JP, et al
    Testosterone Therapy in Men With Prostate Cancer.
    Eur Urol. 2015 Dec 21. pii: S0302-2838(15)01213.
    PubMed     Text format     Abstract available


  498. TILKI D, Evans CP
    Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few.
    Eur Urol. 2015 Dec 21. pii: S0302-2838(15)01216.
    PubMed     Text format    


  499. BRYANT HE
    The Clinical Impact of BRCA2 Loss in Prostate Cancer.
    Eur Urol. 2015 Dec 18. pii: S0302-2838(15)01217.
    PubMed     Text format    


  500. LANGLEY RE, Kynaston HG, Alhasso AA, Duong T, et al
    A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
    Eur Urol. 2015 Dec 17. pii: S0302-2838(15)01201.
    PubMed     Text format     Abstract available


  501. ALBERTSEN PC, Lu-Yao GL
    Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men Aged 6
    Eur Urol. 2015 Dec 16. pii: S0302-2838(15)01202.
    PubMed     Text format    


  502. YAP T, Ahmed HU, Hindley RG, Guillaumier S, et al
    Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.014: Focal Therapy
    Eur Urol. 2015 Dec 13. pii: S0302-2838(15)01208.
    PubMed     Text format    


  503. VAN DEN BERGH RC, van Casteren NJ, van den Broeck T, Fordyce ER, et al
    Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
    Eur Urol. 2015 Dec 12. pii: S0302-2838(15)01178.
    PubMed     Text format     Abstract available


  504. HENDERSON DR, de Souza NM, Parker CC, van As NJ, et al
    Reply from Authors re: Tillmann Loch, Pat Fox Fulgham. Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.015: Imaging in Active Surveillance f
    Eur Urol. 2015 Dec 11. pii: S0302-2838(15)01188.
    PubMed     Text format    


  505. SRIDHAR SS, Sweeney CJ
    It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2015 Dec 9. pii: S0302-2838(15)01186.
    PubMed     Text format    


  506. FROEHNER M, Koch R, Wirth MP
    Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805-11.
    Eur Urol. 2015 Dec 9. pii: S0302-2838(15)01203.
    PubMed     Text format    


  507. IGLESIAS-GATO D, Wikstrom P, Tyanova S, Lavallee C, et al
    The Proteome of Primary Prostate Cancer.
    Eur Urol. 2015 Dec 2. pii: S0302-2838(15)01087.
    PubMed     Text format     Abstract available


  508. LOCH T, Fulgham PF
    Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow.
    Eur Urol. 2015 Dec 1. pii: S0302-2838(15)01165.
    PubMed     Text format    


    November 2015
  509. WALLIS CJ, Saskin R, Choo R, Herschorn S, et al
    Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2015 Nov 30. pii: S0302-2838(15)01160.
    PubMed     Text format     Abstract available


  510. BOURKE L, Smith D, Steed L, Hooper R, et al
    Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2015 Nov 26. pii: S0302-2838(15)01081.
    PubMed     Text format     Abstract available


  511. KHANI F, Robinson BD
    A "Chicken or Egg" Conundrum: Race, Molecular Subtype, and Tumor Location in Prostate Cancer.
    Eur Urol. 2015 Nov 25. pii: S0302-2838(15)01162.
    PubMed     Text format    


  512. GRAVIS G, Boher JM, Joly F, Soulie M, et al
    Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Eur Urol. 2015 Nov 20. pii: S0302-2838(15)01103.
    PubMed     Text format     Abstract available


  513. EGEVAD L, Delahunt B, Samaratunga H, Srigley JR, et al
    Utility of Reporting the Percentage of High-grade Prostate Cancer.
    Eur Urol. 2015 Nov 19. pii: S0302-2838(15)01158.
    PubMed     Text format    


  514. SHAW GL, Whitaker H, Corcoran M, Dunning MJ, et al
    The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.
    Eur Urol. 2015 Nov 10. pii: S0302-2838(15)01076.
    PubMed     Text format     Abstract available


  515. WALLIS CJ, Mahar A, Cheung P, Herschorn S, et al
    New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men.
    Eur Urol. 2015 Nov 10. pii: S0302-2838(15)01077.
    PubMed     Text format     Abstract available


  516. RUBIN MA, Girelli G, Demichelis F
    Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.
    Eur Urol. 2015 Nov 9. pii: S0302-2838(15)01074.
    PubMed     Text format     Abstract available


  517. BOLLA M
    Re: Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them.
    Eur Urol. 2015;68:909-10.
    PubMed     Text format    


    September 2015
  518. LA VECCHIA C
    Finasteride and Bladder Cancer.
    Eur Urol. 2015 Sep 10. pii: S0302-2838(15)00858.
    PubMed     Text format    


  519. FAURE WALKER N, Nair R, Anderson C
    Re: Gunnar Steineck, Anders Bjartell, Jonas Hugosson, et al. Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. Eur Urol 2015;67:559-68.
    Eur Urol. 2015;68:e63.
    PubMed     Text format    


    August 2015
  520. IRANI J
    Re: Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomized Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists.
    Eur Urol. 2015;68:339.
    PubMed     Text format    


    July 2015
  521. KAMRAVA M
    Re: Ian A. Donaldson, Roberto Alonzi, Dean Barratt, et al. Focal Therapy: Patients, Interventions, and Outcomes-A Report from a Consensus Meeting. Eur Urol 2015;67:771-7.
    Eur Urol. 2015;68:e14.
    PubMed     Text format    


  522. TILKI D, Huland H, Graefen M
    Centralization and Quality Control of Elective Surgery Improve Outcome: Aren't We Ethically Obliged to Force the Pace of Creating High-volume Centers?
    Eur Urol. 2015;68:30-1.
    PubMed     Text format    


  523. AUTORINO R, Zargar H, Porpiglia F
    Reply to Francesco Montorsi and Giorgio Gandaglia's Letter to the Editor re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-instituti
    Eur Urol. 2015;68:e9-10.
    PubMed     Text format    


  524. MONTORSI F, Gandaglia G
    Re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol 2015;68:86-94Re: Matthew Bultitude, Ben Challacom
    Eur Urol. 2015;68:e7-8.
    PubMed     Text format    


  525. BULTITUDE M, Challacombe B
    Simple Prostatectomy: A Step Too Far for Laparoscopy?
    Eur Urol. 2015;68:95-6.
    PubMed     Text format    


  526. AUTORINO R, Zargar H, Mariano MB, Sanchez-Salas R, et al
    Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis.
    Eur Urol. 2015;68:86-94.
    PubMed     Text format     Abstract available


  527. LOEB S
    Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for "Prime Time"?
    Eur Urol. 2015;68:20-1.
    PubMed     Text format    


    May 2015
  528. NGUYEN PL, Alibhai SM, Basaria S, D'Amico AV, et al
    Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Eur Urol. 2015;67:825-36.
    PubMed     Text format     Abstract available


  529. ABDOLLAH F, Briganti A, Montorsi F, Stenzl A, et al
    Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.
    Eur Urol. 2015;67:839-49.
    PubMed     Text format     Abstract available


    April 2015
  530. DASGUPTA P
    Improving the evidence for robot-assisted radical prostatectomy.
    Eur Urol. 2015;67:671-2.
    PubMed     Text format    


  531. HOGLUND M
    Heterogeneous challenges for urologic cancers.
    Eur Urol. 2015;67:738-9.
    PubMed     Text format    


  532. WALLERSTEDT A, Tyritzis SI, Thorsteinsdottir T, Carlsson S, et al
    Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy.
    Eur Urol. 2015;67:660-70.
    PubMed     Text format     Abstract available


    March 2015
  533. HAGLIND E, Carlsson S, Stranne J, Wallerstedt A, et al
    Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial.
    Eur Urol. 2015 Mar 11. pii: S0302-2838(15)00194.
    PubMed     Text format     Abstract available


  534. VAN ALLEN EM, Garraway LA, Rosenberg JE
    Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/
    Eur Urol. 2015 Mar 11. pii: S0302-2838(15)00209.
    PubMed     Text format    


  535. STEINECK G, Bjartell A, Hugosson J, Axen E, et al
    Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery.
    Eur Urol. 2015;67:559-68.
    PubMed     Text format     Abstract available


  536. EHDAIE B, Eastham JA
    Standardization of patient-centered outcomes: less is more.
    Eur Urol. 2015;67:468-9.
    PubMed     Text format    


  537. ZLOTTA AR, Kuk C
    Positive surgical margins: race or surgeon?
    Eur Urol. 2015;67:458-9.
    PubMed     Text format    


  538. ALEMOZAFFAR M, Sanda M, Yecies D, Mucci LA, et al
    Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up Study.
    Eur Urol. 2015;67:432-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: